Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.

Autor: Hieken TJ; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA., Nelson GD; Department of Quantitative Health Sciences, Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA., Flotte TJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Grewal EP; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Chen J; Department of Quantitative Health Sciences, Computational Biology, Mayo Clinic, Rochester, MN, USA., McWilliams RR; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Kottschade LA; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Yang L; Department of Quantitative Health Sciences, Computational Biology, Mayo Clinic, Rochester, MN, USA., Domingo-Musibay E; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA., Dronca RS; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Yan Y; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Markovic SN; Department of Oncology, Mayo Clinic, Rochester, MN, USA.; Department of Immunology, Mayo Clinic, Rochester, MN, USA., Dimou A; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Montane HN; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Erskine CL; Department of Immunology, Mayo Clinic, Rochester, MN, USA., Piltin MA; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA., Price DL; Department of Otolaryngology, Mayo Clinic, Rochester, MN, USA., Khariwala SS; Department of Otolaryngology, University of Minnesota, Minneapolis, MN, USA., Hui J; Division of Surgical Oncology, University of Minnesota, Minneapolis, MN, USA., Strand CA; Department of Quantitative Health Sciences, Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA., Harrington SM; Department of Immunology, Mayo Clinic, Rochester, MN, USA.; Department of Urology, Mayo Clinic, Rochester, MN, USA., Suman VJ; Department of Quantitative Health Sciences, Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA., Dong H; Department of Immunology, Mayo Clinic, Rochester, MN, USA.; Department of Urology, Mayo Clinic, Rochester, MN, USA., Block MS; Department of Oncology, Mayo Clinic, Rochester, MN, USA. block.matthew@mayo.edu.; Department of Immunology, Mayo Clinic, Rochester, MN, USA. block.matthew@mayo.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Feb 16; Vol. 15 (1), pp. 1430. Date of Electronic Publication: 2024 Feb 16.

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.

Autor: Ray U; Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN, USA., Thirusangu P; Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN, USA., Jin L; Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN, USA., Xiao Y; Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China., Pathoulas CL; University of Connecticut Health Center-Medical School, Farmington, CT, USA., Staub J; Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN, USA., Erskine CL; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Dredge K; Zucero Therapeutics, South Melbourne, VIC, Australia., Hammond E; Zucero Therapeutics, South Melbourne, VIC, Australia., Block MS; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Bakkum-Gamez JN; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA., Shridhar V; Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN, USA. shridhar.vijayalakshmi@mayo.edu.

Publikováno v: Oncogene [Oncogene] 2023 Sep; Vol. 42 (37), pp. 2725-2736. Date of Electronic Publication: 2023 Aug 07.

Comparison of replicating and nonreplicating vaccines against SARS-CoV-2.

Autor: Mudrick HE; Molecular Pharmacology and Experimental Therapeutics (MPET) Graduate Program, Mayo Clinic, Rochester, MN, USA., Massey S; Center of Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA., McGlinch EB; Graduate Research Education Program (GREP), Mayo Clinic, Rochester, MN, USA.; Virology and Gene Therapy (VGT) Graduate Program, Mayo Clinic, Rochester, MN, USA., Parrett BJ; Graduate Research Education Program (GREP), Mayo Clinic, Rochester, MN, USA.; Virology and Gene Therapy (VGT) Graduate Program, Mayo Clinic, Rochester, MN, USA., Hemsath JR; Graduate Research Education Program (GREP), Mayo Clinic, Rochester, MN, USA.; Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA., Barry ME; Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA., Rubin JD; Virology and Gene Therapy (VGT) Graduate Program, Mayo Clinic, Rochester, MN, USA., Uzendu C; Virology and Gene Therapy (VGT) Graduate Program, Mayo Clinic, Rochester, MN, USA., Hansen MJ; Department of Immunology, Mayo Clinic, Rochester, MN, USA., Erskine CL; Department of Immunology, Mayo Clinic, Rochester, MN, USA., Van Keulen VP; Department of Immunology, Mayo Clinic, Rochester, MN, USA., Drelich A; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA., Panos JA; Rehabilitation Medicine Research Center, Musculoskeletal Gene Therapy Research Laboratory, Mayo Clinic Medical Scientist Training Program, Mayo Clinic, Rochester, MN, USA., Fida M; Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA., Suh GA; Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA., Peikert T; Department of Immunology, Mayo Clinic, Rochester, MN, USA.; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.; Department of Medicine, Division of Pulmonary Care, Mayo Clinic, Rochester, MN, USA., Block MS; Department of Immunology, Mayo Clinic, Rochester, MN, USA.; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Tseng CK; Center of Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.; Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, USA., Olivier GR; Mayo Clinic Ventures, Mayo Clinic, Rochester, MN, USA., Barry MA; Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA.; Department of Immunology, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Publikováno v: Science advances [Sci Adv] 2022 Aug 26; Vol. 8 (34), pp. eabm8563. Date of Electronic Publication: 2022 Aug 24.

Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection.

Autor: Robison HM; Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, MI, USA., Chapman CA; Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, MI, USA., Zhou H; Department of Statistics, University of Illinois Urbana-Champaign, 725 South Wright Street, Champaign, IL, USA., Erskine CL; Department of Immunology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Theel E; Department of Laboratory Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Peikert T; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA., Lindestam Arlehamn CS; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Sette A; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.; Department of Medicine, University of California San Diego, La Jolla, CA, USA., Bushell C; National Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, 1205 W. Clark St., Urbana, IL, USA., Welge M; National Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, 1205 W. Clark St., Urbana, IL, USA., Zhu R; Department of Statistics, University of Illinois Urbana-Champaign, 725 South Wright Street, Champaign, IL, USA., Bailey RC; Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, MI, USA., Escalante P; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. escalante.patricio@mayo.edu.

Publikováno v: Scientific reports [Sci Rep] 2021 Oct 15; Vol. 11 (1), pp. 20544. Date of Electronic Publication: 2021 Oct 15.